Press Releases

Press Releases

Another Patient Victory: Federal Court Rejects BMS and Janssen’s Case Against Medicare Negotiation

WASHINGTON, D.C. — This morning, the U.S. Court of Appeals For The Third Circuit rejected Bristol Myers Squibb (BMS) and Janssen’s challenge to the Medicare Drug Price Negotiation Program, standing with patients and affirming the earlier district court decision that the program is constitutional. Following pharma’s three legal defeats in August, this latest decision marks the 13th ruling in favor of […]

Press Releases

ICYMI: Courts Deliver Three Major Legal Wins for Medicare Drug Price Negotiation in Just Two Days

WASHINGTON, D.C. — Over the span of just 48 hours, three federal courts delivered resounding defeats to Big Pharma’s legal campaign to overturn the Medicare Drug Price Negotiation Program — marking the 10th, 11th, and 12th rulings in favor of patients and the law that’s set to deliver lower drug prices to 9 million people on […]

Press Releases

Federal Court Delivers Another Defeat To Big Pharma’s Legal Attacks On Medicare Negotiation, Rejects Boehringer Ingelheim’s Challenge

The U.S. Court of Appeals for the Second Circuit stood with a lower court’s 2024 decision ruling against Boehringer Ingelheim WASHINGTON, D.C. — In yet another decisive win for patients, the U.S. Court of Appeals for the Second Circuit rejected Boehringer Ingelheim’s attempt to block Medicare’s authority to negotiate lower drug prices. This marks the second win in less than 24 […]

Press Releases

PHARMA DEFEAT: Federal Court Rejects U.S. Chamber of Commerce’s Case Against Medicare Negotiation

The U.S. Court of Appeals for the Sixth Circuit stood with the lower court’s 2024 decision to dismiss the U.S. Chamber of Commerce’s Case   WASHINGTON, D.C. — In another blow to pharma’s multi-million dollar legal campaign against the Medicare Negotiation Program, today the Sixth Circuit U.S. Court of Appeals blocked a legal challenge to […]

Press Releases

ICYMI: New Study Shatters Pharma’s Claims About IRA: Drug R&D Spending Hit Record Highs After Law’s Passing

Analysis found that drug research spending “increased to record levels” in the six quarters following the IRA’s passage in 2022 WASHINGTON, D.C. — New analysis from Bentley University demolishes Big Pharma’s core talking point that Medicare negotiation would kill drug research and development (R&D). The study found that after flatlining from 2020 to 2022, drug […]

Press Releases

ICYMI: P4AD Releases Report Exposing Six Pharma-Funded Front Groups Keeping Drug Prices High

WASHINGTON, D.C. — Last week, Patients For Affordable Drugs released a new report, The Rampant Reach of Pharma’s Hidden Hand, uncovering the pharmaceutical industry’s efforts to fund, influence — and in some cases, fully operate — front groups that claim to represent the interests of patients while working to protect drug company profits. Each of […]

Press Releases

New P4AD Report Exposes Big Pharma-Funded Front Groups Undermining The Fight To Lower Prescription Drug Prices

Third iteration of Hidden Hand report aimed at helping policymakers and media gain a clearer picture of pharma-aligned groups WASHINGTON, D.C. — Today, Patients For Affordable Drugs is releasing a new report, The Rampant Reach of Pharma’s Hidden Hand, uncovering the pharmaceutical industry’s latest efforts to fund, influence — and in some cases, fully operate — front […]

Press Releases

STATEMENT: Patients For Affordable Drugs Applauds Third Circuit Decision Upholding Medicare Drug Price Negotiation In Another Win for Patients

WASHINGTON, D.C. —Today, the U.S. Court of Appeals for the Third Circuit rejected AstraZeneca’s challenge to the Medicare Drug Price Negotiation Program. The unanimous ruling marks the first appellate decision to evaluate and uphold the legality of the program’s core framework, dealing a major blow to pharmaceutical industry efforts to block lower drug prices. Patients For […]